Tumor Genomic Biomarkers as Prognostic Modifiers of Outcomes Following CD19 CAR T-Cell Therapy in Aggressive Large B-Cell Lymphoma: A Systematic Review and Exploratory Meta-Analysis.
Yang Jingke, Hatcher Heather, Kulkarni Harshad, +1 more·Genes
: Outcomes after CD19-directed chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory (R/R) aggressive large B-cell lymphoma (aLBCL) remain heterogeneous. Tumor genomic biomarkers, such as TP53 alteration, MYC/BCL2/BCL6 rearrangement-defined double-hit or triple-hit lymphoma (DHL/THL), cell of origin…